Ophthalmic Drugs Market (Disease Indication: Dry Eye, Glaucoma, Infection/Inflammation, Retinal Disorders, Allergy, Uveitis, and Others; and Product Type: Prescription Drugs and OTC Drugs) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Oct 2022| TMR3418A| Transparency

Report Highlights

Ophthalmic Drugs Market – Scope of Report

TMR’s report on the global ophthalmic drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ophthalmic drugs market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ophthalmic drugs market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ophthalmic drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ophthalmic drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ophthalmic drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ophthalmic drugs market.

The report delves into the competitive landscape of the global ophthalmic drugs market. Key players operating in the global ophthalmic drugs market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ophthalmic drugs market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ophthalmic drugs.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

  • Company websites, presentations, annual reports, white papers, technical paper, product brochure
  • Internal and external proprietary databases and relevant patents
  • National government documents, statistical databases, and market reports
  • News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

  • Industry Sources:
  • WorldWideScience.org
  • Elsevier, Inc.
  • National Institutes of Health (NIH)
  • PubMed
  • NCBI
  • Department of Health Care Service
  • Trade Data Sources
  • Trade Map
  • UN Comtrade
  • Trade Atlas
  • Company Information
  • OneSource Business Browser
  • Hoover’s
  • Factiva
  • Bloomberg
  • Mergers & Acquisitions
  • Thomson Mergers & Acquisitions
  • MergerStat
  • Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

  • Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
  • Helps in validating and strengthening secondary research findings
  • Further develops the analysis team’s expertise and market understanding
  • Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

  • Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
  • Purchasing/Sourcing managers, technical personnel, distributors
  • Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
  • Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

  • Advanced Oncotherapy PLC
  • Danfysik A/S
  • Hitachi, Ltd.
  • IBA Worldwide
  • Mevion Medical Systems, Inc.

Report Synopsis

Report Metrics Details
Base year considered 2022
Forecast period considered 2022-2031
Growth rate 6.83%
Units considered $ Million
Segments covered By Disease Indication, By Therapeutic Class, By Product Type, By Distribution Channel, By Region
Industry covered Pharmaceutical
Countries covered North America, Europe, Asia Pacific, Middle East & Africa, Latin America
Companies studied
  • Aerie Pharmaceuticals, Inc.,
  • Genentech, Inc. (F. Hoffmann-La Roche Ltd.),
  • Allergan plc,
  • Valeant Pharmaceuticals International, Inc.,
  • Bayer AG,
  • Regeneron Pharmaceuticals, Inc.,
  • Novartis AG,
  • Pfizer Inc.,
  • Santen Pharmaceutical Co., Ltd.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others

Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

  • Table 1 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
  • Table 2 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2017–2031
  • Table 3 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2031
  • Table 4 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017–2031
  • Table 5 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017–2031
  • Table 6 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017–2031
  • Table 7 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
  • Table 8 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 9 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
  • Table 10 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
  • Table 11 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
  • Table 12 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2017–2031
  • Table 13 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2031
  • Table 14 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017–2031
  • Table 15 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017–2031
  • Table 16 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017–2031
  • Table 17 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
  • Table 18 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2031
  • Table 19 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
  • Table 20 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
  • Table 21 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, Ophthalmic Drugs Market Forecast, by Disease Indication – Retinal Disorder, 2017–2031
  • Table 22 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2031
  • Table 23 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drug, 2017–2031
  • Table 24 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drug, 2017–2031
  • Table 25 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drug, 2017–2031
  • Table 26 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
  • Table 27 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 28 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 29 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
  • Table 30 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2017–2031
  • Table 31 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2031
  • Table 32 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2017–2031
  • Table 33 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2017–2031
  • Table 34 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2017–2031
  • Table 35 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
  • Table 36 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 37 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
  • Table 38 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
  • Table 39 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication – Retinal Disorder, 2017–2031
  • Table 40 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2031
  • Table 41 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-inflammatory Drugs, 2017–2031
  • Table 42 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-infective Drugs, 2017–2031
  • Table 43 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class – Anti-glaucoma Drugs, 2017–2031
  • Table 44 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
  • Table 45 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Table 46 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031
  • Table 47 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication, 2017–2031
  • Table 48 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Disease Indication - Retinal Disorders, 2017–2031
  • Table 49 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class, 2017–2031
  • Table 50 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-inflammatory Drugs, 2017–2031
  • Table 51 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-infective Drugs, 2017–2031
  • Table 52 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Therapeutic Class - Anti-glaucoma Drugs, 2017–2031
  • Table 53 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
  • Table 54 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
  • Figure 1 : Global Ophthalmic Drugs Market Value (US$ Mn) Forecast, 2017–2031
  • Figure 2 : Global Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2031
  • Figure 3 : Global Ophthalmic Drugs Market Value Share, by Disease Indication, 2017–2031
  • Figure 4 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Dry Eye, 2017–2031
  • Figure 5 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Glaucoma, 2017–2031
  • Figure 6 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Infection/Inflammation, 2017–2031
  • Figure 7 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Retinal Disorders, 2017–2031
  • Figure 8 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Uveitis, 2017–2031
  • Figure 9 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Allergy, 2017–2031
  • Figure 10 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Other Ophthalmic Diseases, 2017–2031
  • Figure 11 : Global Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2031
  • Figure 12 : Global Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017–2031
  • Figure 13 : Global Ophthalmic Drugs Market, by Anti-infective Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 14 : Global Ophthalmic Drugs Market, by Anti-inflammatory Drugs Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 15 : Global Ophthalmic Drugs Market, by Anti-glaucoma Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 16 : Global Ophthalmic Drugs Market, by Anti-VEGF Agents, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 17 : Global Ophthalmic Drugs Market, by Anti-allergy Drugs, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 18 : Global Ophthalmic Drugs Market, by Others, Revenue (US$ Mn) and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 19 : Global Ophthalmic Drugs Market Value Share, by Product Type, for 2017–2031
  • Figure 20 : Global Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2031
  • Figure 21 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Prescription Drugs, 2017–2031
  • Figure 22 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by OTC Drugs, 2017–2031
  • Figure 23 : Global Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017–2031
  • Figure 24 : Global Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2031
  • Figure 25 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Online Pharmacies, 2017–2031
  • Figure 26 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Hospital Pharmacies, 2017–2031
  • Figure 27 : Global Ophthalmic Drugs Market Revenue (US$ Mn) and Y-o-Y Growth Projection (%), by Independent Pharmacies & Drug Stores, 2017–2031
  • Figure 28 : Global Ophthalmic Drugs Market Value Share, by Region, for 2017–2031
  • Figure 29 : Global Ophthalmic Drugs Market Attractiveness, by Region, 2017–2031
  • Figure 30 : North America Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 31 : North America Ophthalmic Drugs Market Attractiveness, by Country, 2017–2031
  • Figure 32 : North America Ophthalmic Drugs Market Value Share, by Country, 2017–2031
  • Figure 33 : North America Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2017–2031
  • Figure 34 : North America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017–2031
  • Figure 35 : North America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017–2031
  • Figure 36 : North America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2031
  • Figure 37 : North America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017–2031
  • Figure 38 : North America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2031
  • Figure 39 : North America Ophthalmic Drugs Market Value Share, by Distribution Channels, 2017–2031
  • Figure 40 : North America Ophthalmic Drugs Market Attractiveness, by Distribution Channels, 2017–2031
  • Figure 41 : Europe Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 42 : Europe Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017–2031
  • Figure 43 : Europe Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017–2031
  • Figure 44 : Europe Ophthalmic Drugs Market Attractiveness, By Disease Indication, 2015-2025
  • Figure 45 : Europe Ophthalmic Drugs Market Value Share, by Disease Indication, 2017–2031
  • Figure 46 : Europe Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017–2031
  • Figure 47 : Europe Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2031
  • Figure 48 : Europe Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017–2031
  • Figure 49 : Europe Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2031
  • Figure 50 : Europe Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017–2031
  • Figure 51 : Europe Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2031
  • Figure 52 : Asia Pacific Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
  • Figure 53 : Asia Pacific Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017–2031
  • Figure 54 : Asia Pacific Ophthalmic Drugs Market Value Share, by Country/Sub-region, for 2017–2031
  • Figure 55 : Asia Pacific Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2031
  • Figure 56 : Asia Pacific Ophthalmic Drugs Market Value Share, by Disease Indication, for 2017–2031
  • Figure 57 : Asia Pacific Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2031
  • Figure 58 : Asia Pacific Ophthalmic Drugs Market Value Share, by Therapeutic Class, for 2017–2031
  • Figure 59 : Asia Pacific Ophthalmic Drugs Market Value Share Analysis, by Product Type, for 2017–2031
  • Figure 60 : Asia Pacific Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2031
  • Figure 61 : Asia Pacific Ophthalmic Drugs Market Value Share, by Distribution Channel, for 2017–2031
  • Figure 62 : Asia Pacific Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2031
  • Figure 63 : Latin America Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 64 : Latin America Ophthalmic Drugs Market Attractiveness, by Country/Sub-region, 2017–2031
  • Figure 65 : Latin America Ophthalmic Drugs Market Value Share, by Country/Sub-region, 2017–2031
  • Figure 66 : Latin America Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2031
  • Figure 67 : Latin America Ophthalmic Drugs Market Value Share, by Disease Indication, 2017–2031
  • Figure 68 : Latin America Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2031
  • Figure 69 : Latin America Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017–2031
  • Figure 70 : Latin America Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017–2031
  • Figure 71 : Latin America Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2031
  • Figure 72 : Latin America Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017–2031
  • Figure 73 : Latin America Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2031
  • Figure 74 : Middle East & Africa Ophthalmic Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2017–2031
  • Figure 75 : Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Country/Sub-Region, 2017–2031
  • Figure 76 : Middle East & Africa Ophthalmic Drugs Market Value Share, by Country/Sub-Region, 2017–2031
  • Figure 77 : Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Disease Indication, 2017–2031
  • Figure 78 : Middle East & Africa Ophthalmic Drugs Market Value Share, by Disease Indication, 2017–2031
  • Figure 79 : Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Therapeutic Class, 2017–2031
  • Figure 80 : Middle East & Africa Ophthalmic Drugs Market Value Share, by Therapeutic Class, 2017–2031
  • Figure 81 : Middle East & Africa Ophthalmic Drugs Market Value Share Analysis, by Product Type, 2017–2031
  • Figure 82 : Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Product Type, 2017–2031
  • Figure 83 : Middle East & Africa Ophthalmic Drugs Market Value Share, by Distribution Channel, 2017–2031
  • Figure 84 : Middle East & Africa Ophthalmic Drugs Market Attractiveness, by Distribution Channel, 2017–2031
  • Figure 85 : Global Ophthalmic Drugs Market Share, by Company, 2016

Leaders in analytics, research and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a prominent provider of a cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who had a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence.

Transparency
Price: $5795

Become a Member

Already a member? Login here.

Have a Question? Ask Us.

Why BCC Research?

Every purchase provides access to:

  • Thousands of recently published reports from select publishers
  • Member Discounts of up to 50% on over 20,000 additional reports from all publishers
  • Our analysts and research concierge for all inquiries
Custom Research

Need a custom data table, graph or complete report? Tell us more.

RELATED REPORTS